1.基本信息
V. Wee Yong, 男，1957年生，博士，加拿大皇家科学院与健康科学院院士，加拿大卡尔加里大学教授，郑州大学特聘教授，主要研究方向为神经病学与神经免疫。
电子邮箱：vyong@ucalgary.ca
2.专业领域
多发性硬化，神经免疫，脊髓损伤，脑出血，神经修复与再生
3.学术任职
2014 加拿大皇家科学院院士
2010 加拿大健康科学院院士
2014-2016 国际神经免疫学会主席
2012-2014 国际神经免疫学会副主席
2004-至今 加拿大神经免疫学研究主席
1998-2003 加拿大卫生研究所科学家
1998-2003 艾伯塔省医学研究遗传基金会高级学者
1989-1994 加拿大医学研究理事会学者
4.学术荣誉
2017年 泰勒国际医学奖
2016年 卡尔加里大学史密斯杰出奖
2015年 卡尔加里大学顶尖学者
2012-2013 Killam年度教授
2009年 卡尔加里大学“U make a difference”奖
2007年 加拿大多发性硬化症协会国家荣誉证书
2005-2009年 艾伯塔省传统医学研究基金会医学科学家
2002年 因多发性硬化症志愿者活动获伊丽莎白二世女王加拿大黄金纪念章
2000年 加拿大多发性硬化症协会国家杰出贡献奖
2000年 卡尔加里大学医学院研究杰出成就卓越奖
5.主持或参加的课题
2019/7 - 2026/6
Principal Applicant
Harnessing neuro-inflammation to develop new treatments for Multiple Sclerosis and
glioblastoma.
Funding Sources:
2019/7 - 2027/6 Canadian Institutes of Health Research (CIHR)
Foundation Grant
Total Funding - 5,784,461 (Canadian dollar)
Funding Competitive?: Yes
2020/1 - 2025/12
Co-applicant
Canadian Progression Cohort in MS (CanProCo).
Funding Sources:
2019/3 - 2024/4 Multiple Sclerosis Society of Canada
Operating grant
Total Funding - 80,000 (Canadian dollar)
Funding Competitive?: Yes
2023/1 - 2025/12
Co-investigator
Micro and mesoscale imaging of neurodegeneration and repair in MS
Funding Sources:
2023/1 - 2025/12 Canada Foundation for Innovation (CFI)
Equipment
Total Funding - 4,497,691 (Canadian dollar)
Funding Competitive?: Yes
2022/5 - 2025/6
Principal Applicant
Defining and Overcoming a Novel Extracellular Matrix Inhibitor of Remyelination in MS:
Fibulin-2
Co-investigator : Dr. C. C. Ling
Funding Sources:
2022/7 - 2025/6 Department of Defense (USA)
Congressionally Directed Multiple Sclerosis Research Program
Total Funding - 200,000 (United States dollar)
Funding Competitive?: Yes
Completed [n=16]
2018/4 - 2023/3
Principal Applicant
Mobilizing anti-tumor microglia/macrophages with niacin to improve the prognosis of
glioblastoma: Bench to clinical trial and back
Co-applicant : Dr. Gloria Roldan-Urgoiti; Dr. Jeff Dunn; Dr. John Kelly; Dr. Paula deRobles
Funding Sources:
2018/4 - 2023/3 Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 1,234,125 (Canadian dollar)
Funding Competitive?: Yes
2020/2 - 2022/12 CSPG targeting for lesion regeneration in multiple sclerosis.
Dr. V. Wee YONG
6
Co-applicant Co-applicant : Bertrand Huard
Funding Sources:
2020/2 - 2022/1 Canadian Institutes of Health Research (CIHR)
International CoEN initiative in neurodegeneration
Total Funding - 200,000 (Canadian dollar)
Funding Competitive?: Yes
2020/11 - 2022/10
Principal Applicant
Unexpected expression of PD1 on brain tumour-initiating cells: a novel regulator of
glioblastoma growth
Funding Sources:
2020/11 - 2022/10 Canadian Cancer Society
Operating Grant
Total Funding - 200,000 (Canadian dollar)
Funding Competitive?: Yes
2019/7 - 2022/6
Principal Applicant
Hierarchy of inhibitors in the lesion microenvironment for remyelination: combining a novel
CNS-targeting therapeutic with exercise to promote repair.
Funding Sources:
2019/7 - 2022/6 Multiple Sclerosis Society of Canada
Operating Grant
Total Funding - 415,613 (Canadian dollar)
Funding Competitive?: Yes
2018/4 - 2021/3
Principal Investigator
Elevated axonal and myelin injury with aging: Mechanisms, prevention and prospective
therapeutics for progressive multiple sclerosis.
Funding Sources:
2018/4 - 2021/3 Multiple Sclerosis Society of Canada
Operating
Total Funding - 420,140 (Canadian dollar)
Funding Competitive?: Yes
2018/1 - 2020/12
Principal Applicant
Pilot trial of niacin in glioblastoma.
Funding Sources:
2018/1 - 2020/12 Hotchkiss Brain Institute Ronald and Irene Ward Foundation
Operating
Total Funding - 200,000 (Canadian dollar)
Funding Competitive?: Yes
2016/6 - 2019/7
Principal Applicant
The genetics of progressive MS.
Funding Sources:
2016/6 - 2019/7 Alberta/Novartis Translational Research Funds
Operating
Total Funding - 300,000 (Canadian dollar)
Funding Competitive?: Yes
2016/7 - 2019/6
Principal Applicant
A new therapeutic target in multiple sclerosis to attenuate neuroinflammation and
neuropathology: the chondroitin sulfate proteoglycans.
Co-applicant : Ling CC
Dr. V. Wee YONG
Funding Sources:
2015/9 - 2020/8 Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 1,016,785 (Canadian dollar)
Funding Competitive?: Yes
2014/4 - 2019/6
Principal Applicant
Defining EMMPRIN as a key regulator of neuroinflammation and neural injury in multiple
sclerosis.
Funding Sources:
2014/4 - 2019/3 Canadian Institutes of Health Research (CIHR)
Operating
Total Funding - 920,750 (Canadian dollar)
Funding Competitive?: Yes
2017/4 - 2019/6
Principal Applicant
Mobilizing anti-tumor microglia/macrophages to improve the prognosis of glioblastoma:
Bench to clinical trial and back.
Co-applicant : Dr. Gloria Roldan-Urgoiti; Dr. John Kelly; Dr. Paula de Robles; Jeff Dunn
Funding Sources:
2017/4 - 2018/4 Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes
2015/7 - 2019/6
Principal Applicant
Rejuvenating deficient re-myelination in aging by harnessing a beneficial inflammatory
response.
Funding Sources:
2015/7 - 2020/6 Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 781,920 (Canadian dollar)
Funding Competitive?: Yes
2018/3 - 2019/4
Principal Applicant
Alberta MS Network 2018 Scientific Forum
Funding Sources:
2018/3 - 2019/2 Canadian Institutes of Health Research (CIHR)
Planning and Dissemination
Total Funding - 20,000 (Canadian dollar)
Funding Competitive?: Yes
2016/4 - 2019/3
Principal Applicant
Mechanisms and parameters of exercise-induced remyelination in mice.
Funding Sources:
2016/4 - 2019/3 Multiple Sclerosis Society of Canada
Operating
Total Funding - 414,136 (Canadian dollar)
Funding Competitive?: Yes
2014/4 - 2019/3
Principal Applicant
Medicines for remyelination in multiple sclerosis: The next frontier
Co-investigator : Dr. Bruce Pike; Dr. Chang-Chun Ling; Dr. Christopher Power; Dr. David
Broadhurst; Dr. Gerlinde Metz; Dr. Jeffrey Dunn; Dr. Luanne Metz; Dr. Marcus Koch; Dr.
Peter Stys; Dr. Yunyan-Zhang
Dr. V. Wee YONG
8
Funding Sources:
2014/4 - 2019/3 Alberta Innovates- Health Solutions
AIHS Crio Team Grant
Total Funding - 5,000,000 (Canadian dollar)
Funding Competitive?: Yes
2017/2 - 2018/12
Principal Applicant
Mechanisms and alleviation of aging-enhanced white matter injury following
demyelination.
Co-investigator : Olga Kovalchuk
Funding Sources:
2017/3 - 2018/3 Alberta MS Collaboration
Operating
Total Funding - 200,000 (Canadian dollar)
Funding Competitive?: Yes
2017/4 - 2018/12
Co-investigator
Bone marrow-derived stem cells mobilization as an acute treatment for spinal cord injury.
Principal Investigator : Dr. Karim Fouad
Funding Sources:
2017/1 - 2018/1 Alberta Spinal Cord Injury Research Fund
Operating
Total Funding - 32,200 (Canadian dollar)
Funding Competitive?: Yes
6.代表性研究成果
2017年发现米诺环素可以减少免疫细胞攻击大脑的三期临床试验用于治疗多发性硬化发表在《新英格兰医学杂志》上（影响因子：79.406）。在 Nature Rev Neurol, Nature Neurosci, Nature aging, Brain 等杂志发表了SCI论文400余篇(其中300 篇为第一或通讯作者），SCI论文引次数超过30,000次。
